Q4 EPS Estimate for Bio-Rad Laboratories Boosted by Analyst

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research boosted their Q4 2024 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research report issued on Thursday, February 6th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.87 per share for the quarter, up from their prior forecast of $2.86. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.33 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $3.16 EPS.

A number of other equities analysts have also recently commented on BIO. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Citigroup upped their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $394.20.

Bio-Rad Laboratories Price Performance

Shares of Bio-Rad Laboratories stock opened at $326.36 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The business’s 50 day simple moving average is $340.91 and its two-hundred day simple moving average is $336.95. The stock has a market capitalization of $9.14 billion, a P/E ratio of -11.94 and a beta of 0.90. Bio-Rad Laboratories has a one year low of $262.12 and a one year high of $387.99.

Hedge Funds Weigh In On Bio-Rad Laboratories

A number of institutional investors have recently added to or reduced their stakes in BIO. Wealthfront Advisers LLC bought a new position in Bio-Rad Laboratories in the fourth quarter worth $342,686,000. Van ECK Associates Corp grew its stake in shares of Bio-Rad Laboratories by 97.8% in the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after acquiring an additional 644,530 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Bio-Rad Laboratories in the third quarter worth $83,681,000. Wedge Capital Management L L P NC purchased a new stake in shares of Bio-Rad Laboratories in the fourth quarter worth $28,740,000. Finally, Mawer Investment Management Ltd. grew its stake in shares of Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after acquiring an additional 84,237 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.